ESR1 and breast cancer: For example, according to published data (Hu et al., 2021), pathogenic variants in BARD1, RAD51C, and RAD51D were statistically likely associated with an increased risk of estrogen-receptor-negative and triple-negative forms of breast cancer, whereas pathogenic variants in ATM, CDH1, and CHEK2 were associated with an increased risk of estrogen-receptor-positive breast cancer.